NDM-1 gene discovered in Delhi
British researchers identify the New Delhi metallo-beta-lactamase resistance gene in patients returning from India, triggering global alarm over Indian-origin superbugs.
India consumes more antibiotics than any country on Earth. Superbugs resistant to last-resort drugs kill 58,000 Indian newborns every year. The post-antibiotic era may arrive here first.
Audio version coming soon
India is now the global epicentre of antimicrobial resistance. A 2024 Lancet study estimated that drug-resistant infections directly kill about 3 lakh Indians every year and contribute to nearly 10 lakh deaths overall. The country consumes more antibiotics than any other, and over-the-counter sales without prescription remain common. Neonatal intensive care units at AIIMS, KEM Mumbai and PGI Chandigarh routinely report that 60 to 70 percent of bacterial infections in newborns are resistant to first-line antibiotics. Even carbapenems, considered the last line, fail in roughly a third of hospital-acquired Klebsiella cases. The drivers range from livestock antibiotic use and unregulated pharmacy sales to inadequate sewage treatment and weak infection control inside hospitals. Without urgent action, common infections, childbirth and routine surgery could become high-risk procedures in Indian hospitals within a decade.
Three forces have driven India's resistance crisis. First, antibiotics are sold openly without prescription across most pharmacies, despite Schedule H1 rules requiring a doctor's slip. A patient with a viral fever often walks out with three days of azithromycin. Second, livestock and aquaculture use antibiotics as growth promoters and routine feed additives, releasing resistant bacteria into water and soil. ICAR studies have found multi-drug resistant E coli in close to 70 percent of broiler chicken samples. Third, hospitals themselves drive resistance through inconsistent infection control. ICMR's antimicrobial resistance surveillance network has reported steady year-on-year rises in carbapenem-resistant Klebsiella and Acinetobacter, especially in tertiary care. Underneath all this sits an unfinished sanitation system. Hospital effluent and pharma manufacturing waste in Hyderabad and Gujarat industrial zones still flow into rivers, seeding resistance genes in the wider environment.
Unread picks stay on top. Fresh stories may appear as they are ready โ no extra loading.
India now has 12 million obese children under 19, according to ICMR data. School canteens sell junk food while ultra-processed food advertising targets children.
India collects only 11 million units of blood annually against a need of 15 million. The O-negative shortage is acute, urban blood banks run on single-day reserves, and the rural gap is catastrophic.
India has fewer sports medicine doctors than many US college programs. Cricket and marathons grew fast; specialist care did not, so preventable injuries end careers early.
Biosimilars โ cheaper copies of complex biological drugs โ are worth 50 billion globally. Indian companies are racing to capture that market, threatening to cut the price of cancer and.
Micronutrient gaps hit rich and poor: anaemia stays high, vegetarians often lack B12, and urban adults lack vitamin D. Fortification and better diets can bend the curve if delivery improves.
127 essential medicines are out of stock in government hospitals across 12 states. The shortage hits insulin, antibiotics and cancer drugs. Central procurement failure exposes PM Jan Aushadhi gaps.
Key data on antimicrobial resistance in India:
Myth 1: Antibiotics treat viral fevers and colds. Fact: Antibiotics work only on bacteria, not viruses. A typical viral fever, sore throat or seasonal flu does not need them. Taking azithromycin or amoxicillin for viral illness kills only the bystander bacteria in the gut and selects for resistant strains. ICMR's stewardship guidelines note that the majority of outpatient antibiotic prescriptions in India are unnecessary.
Myth 2: Stop the course as soon as you feel better, to save the drug. Fact: Stopping early can leave partially treated bacteria alive, which then evolve resistance. Doctors do increasingly prescribe shorter regimens, but the duration must be the one chosen for that disease and patient, not the moment the fever falls.
Myth 3: Resistance is a problem of cheap generic drugs, not branded ones. Fact: Resistance is a problem of how much we use, not which brand. India's high-end private hospitals see the highest carbapenem resistance rates because they prescribe these last-line drugs the most. Branded or generic, the bacteria do not care.
Take baby Aarav, born premature at a Lucknow government hospital in 2024. He developed sepsis on day five and his doctors moved through four antibiotics in eleven days before a final colistin-based combination worked. His family spent 2.4 lakh rupees, more than a year's income. Stories like Aarav's are now routine. A 2023 PGI Chandigarh audit of NICU sepsis showed 64 percent of bacteria isolated were resistant to all first-line drugs. Adults face the same trap. Diabetics with foot infections in Kolkata's tertiary hospitals often need eight to twelve weeks of expensive intravenous therapy where, a decade ago, two weeks of oral tablets would have sufficed. Elderly patients undergoing routine procedures like hip replacements or gallbladder surgery are now warned that hospital-acquired infection can be both fatal and almost untreatable. The hidden cost is silence, because resistant infections rarely make headlines but they reshape what doctors can promise.
The deeper meaning of India's AMR crisis is that it threatens the very base of modern medicine. Caesarean births, organ transplants, chemotherapy and even minor surgery rely on effective antibiotics to manage infection. As resistance spreads, every one of these becomes more dangerous and more expensive. The long-term consequence is not just more deaths, but a reversal of medical progress in this country. India can still bend the curve. Countries like the Netherlands and Norway show that aggressive stewardship, hospital surveillance and tight regulation of agricultural antibiotic use can keep resistance rates low. The lesson is that AMR is not an inevitable fate but a policy choice. India must enforce Schedule H1, fund infection control teams at every district hospital, ban livestock growth-promoting antibiotics and clean pharma effluent. The future of safe childbirth and routine surgery here depends on whether AMR is treated as the slow national emergency it has already become.
Chronology
Follow the arc from background to turning points. On mobile, swipe the cards and use the step rail below; on desktop, use the spine to jump.
British researchers identify the New Delhi metallo-beta-lactamase resistance gene in patients returning from India, triggering global alarm over Indian-origin superbugs.
India introduces Schedule H1 requiring prescriptions for second and third-line antibiotics. Implementation is patchy and many pharmacies continue over-the-counter sales.
India joins the WHO Global Action Plan and sets up surveillance through ICMR's AMRSN network across major tertiary hospitals.
Pandemic-era prescribing pushes azithromycin sales to double the pre-COVID level, accelerating macrolide resistance in respiratory bacteria.
The first comprehensive global estimate of AMR deaths places India among the highest-burden countries, with hundreds of thousands of attributable deaths a year.
Member states commit to cut AMR deaths by 10 percent by 2030. India endorses but its second National Action Plan remains underfunded.
ICMR's 2025 surveillance shows carbapenem resistance in Klebsiella crossing 70 percent in some Indian ICUs, the highest level recorded.
Step 1/7 events
Understand why it happened, how we got here, and what might come next.